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Introduction
The thyroid gland is one of the largest endocrine glands. The 
nervous system, the endocrine, and the immune system are connected 
physiologically and act in a synchronized manner to mediate the body’s 
quick and precise response to environmental stress [1].The thyroid 
gland is found in the neck, below to the thyroid cartilage the isthmus 
the bridge between the two lobes of the thyroid is located inferior to 
the cricoids cartilage. The thyroid gland controls how quickly the body 
uses energy, makes proteins  and controls how sensitive the body is to 
other hormones and proteins for signal transduction; biosynthesis of 
secondary metabolites and those whose function were unknown were 
lowly expressed [2].It participates in these processes by producing 
thyroid hormones, the principal ones being triiodothyronine (T3) and 
thyroxin (T4). These hormones regulate the rate of metabolism and 
affect the growth and rate of function of many other systems in the 
body.
Human thyroid stimulating hormone (TSH) is a glycoprotein 
secreted by the anterior part of the pituitary gland. TSH plays an 
important physiological role in the regulating the hypothalamic-
pituitary-thyroid axis by modulating the release of the thyroid hormones 
from the thyroid gland. It induces iodine uptake by the thyroid, 
promotes thyroid epithelial differentiation and growth, and protects 
thyroid cells from apoptosis. Impairment of TSH signal transduction 
pathway leads to thyroid disorders such as goiter, hypothyroidism and 
hyperthyroidism, which can have complex clinical manifestation [3].
Hypothyroidism is a frequent complication in patients treated for 
head and neck cancer, with reported incidences as high as 52% with 
multimodal therapy. Although hypothyroidism is a known risk factor 
for cardiovascular disease, there is no consensus regarding the impact of 
subclinical hypothyroidism (SCH) on metabolic syndrome (Mets) [4].
Thyroidism is one of the most important causes of preventable mental 
retardation, occurring in approximately 1 in 2000 to 4000 newborn 
infants. With the introduction of a screening program worldwide, it 
was observed that congenital hypothyroidism was associated with a 
higher frequency of extra-thyroidal congenital anomalies compared to 
the normal population [5]. Hypothyroidism is a frequent complication 
in patients treated for head and neck cancer, with reported incidences 
with multimodal therapy [6].
Thyroid cancer is a cancer that starts in the thyroid gland.
Increasing cancer incidence is typically interpreted as an increase in the 
true occurrence of disease but may also reflect changing pathological 
criteria or increased diagnostic scrutiny. Changes in the diagnostic 
approach to thyroid nodules may have resulted in an increase in the 
apparent incidence of thyroid cancer [7]. Head and neck squamous 
cell carcinoma (HSNCC) is highly invasive, frequently metastasizing 
to cervical lymph nodes and corresponds with poor prognosis [8].
Tumor cell invasion and metastasis is a compounding problem in 
cancer management, with therapeutic intervention of tumor invasion 
becoming recognized as an increasingly relevant clinical factor. 
Increased activation of the proto-oncogene c-Src (Src) has been 
established in enhancing tumor progression in human cancer and 
corresponds with poor clinical outcome. Metastasis is the final stage of 
cancer and is still associated with high mortality despite breakthroughs 
in recent years [9].
Types of Thyroid Cancer
Current research on diseases of the ear, nose, throat and related 
structures of the head and neck has experienced significant strides in 
areas including cancer, otology, rhinology and laryngology. Molecular 
diagnostics and advanced imaging modalities including positron 
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Abstract
The thyroid gland produces thyroid hormones which are important in the normal regulation of the metabolism of 
the body. Thyroid cancer is the most common malignancy of the endocrine system consisting of several subtypes 
like papillary carcinoma, and follicular carcinoma, medullary carcinoma, and anaplastic carcinoma. Treatment 
depends on a number of factors, including the type of thyroid cancer, the size of the nodule, the patient’s age, and 
whether the cancer has spread. Most cases of thyroid cancer can be cured with treatment like Radiation therapy 
chemotherapy and radioactive iodine. Recommended thyroid treatment approaches depend on the type of thyroid 
disease, and in some cases, the severity of the condition.
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emission tomography have facilitated diagnosis and patient outcomes. 
Collaborations between physicians and laboratory researchers working 
to identify key clinical issues and translating the biological insights into 
novel therapeutic approaches are crucial to significant progress in the 
field [10].
Thyroid cancer constitutes a heterogeneous group of malignancies 
which exceeds half a million cases annually, ranking it as the fifth most 
common cancer worldwide [11].Head and neck cancers account for 
6% of all cancers worldwide, with nearly 150,000 new cases in Europe 
alone each year. The distribution of primary tumor sites is: oral cavity 
(49%), pharynx (23%) and larynx (28%). Patients with recurrent, 
metastatic disease have a poor prognosis, with a median survival of 
around 6-7 months in addition, patients failing first-line therapy have 
few therapeutic options [12].
Papillary Thyroid cancer
Papillary micro carcinomas are a specific subgroup of papillary 
thyroid cancer. They have the same histological features as papillary 
thyroid cancer but are 1.0 cm or less in diameter. These tumors are a 
common incidental finding at autopsy and in thyroid glands excised for 
other pathology. This tumor can metastasize to regional lymph nodes 
but its ability to cause significant morbidity and mortality has been 
questioned. As papillary micro-carcinomas can represent up to 30 per 
cent of all papillary cancers seen in a thyroid surgeon’s practice, they 
are an important group [13].Lymphangiomas are diffusely infiltrating, 
benign vascular tumors that appear most commonly in the first 2 
decades of life [14]. 
Papillary tumors of the thyroid are the most common form of 
thyroid cancer to result from exposure to radiation. Furthermore, 
clinical response by measurement of tumor size is often discordant 
with the pathological evaluation, such as the clinically response of 
approximately 70% in most studies, the partial or complete regression 
in histopathological biopsy analysis is less than 30% [15]. However, in 
these studies, the diagnostic sensitivity was not sufficiently evaluated 
because of the small number of carcinoma [16].
PTC is common, although it rarely results in disease-specific 
mortality. It is being diagnosed increasingly in the subclinical phase 
as a result of enhanced ultrasound imaging and more aggressive 
surveillance of smaller thyroid nodules [17]. The purpose of this 
study was to review the histological features of proliferative nodules 
and to ascertain the utility of immune histochemistry and analyses 
of oncogenic mutations in signaling components of the MAP kinase 
pathway as diagnostic adjuncts [18] multispectral imaging platform is 
mainly for Tumor-associated change [19].
Papillary thyroid cancer (PTC), the most common thyroid 
malignancy, is associated with an excellent prognosis. Overall survival 
is more than 90%. The first-line treatment is surgical excision, and 
although the debate continues as to whether a total thyroidectomy or 
thyroid lobectomy should be recommended, the treatment options 
that are chosen depend on patient factors, disease factors, and the 
decisions of the patient and treatment team [20]. Surgery is currently 
the only tested treatment option to cure papillary thyroid cancer. Most 
people can be cured by surgical removal of the thyroid gland. Once 
the diagnosis of papillary thyroid cancer has been made by fine needle 
aspiration biopsy, surgery is indicated in order to remove the tumor.
Follicular Thyroid cancer
Follicular thyroid cancer of the thyroid gland accounts for between 
4% and 39% of all malignant thyroid tumors. Follicular carcinoma 
is more common in women who are affected over a broad age range 
[21].Cancer is basically a cell disease, characterized by a loss in the 
mechanisms which drive the proliferation and cellular differentiation 
[22]. The cells were cultured and the proliferation was assessed by cell 
counting using a haemocytometer after trypsin digestion [23].
Follicular thyroid carcinoma (FTC) is a well-differentiated tumor. 
In fact, FTC resembles the normal microscopic pattern of the thyroid. 
FTC originates in follicular cells and is the second most common cancer 
of the thyroid, after papillary carcinoma. Patients with differentiated 
thyroid cancer generally have a good prognosis and high cure rates; 
however, subgroups of patients exist who develop progressive disease 
with significant morbidity and mortality. The clinical outcome of 
patients with follicular thyroid cancer and distant metastases to define 
their presentation, impact of therapy and clinical outcome [24] .Genetic 
factors may also have a role in determining disease susceptibility 
but remain ill-defined. Histological, FTC is characterized by follicle 
formation and the absence of any papillary elements in the tumor. 
Differential diagnosis of a   carcinoma can be difficult [25].
Tumors are rarely encountered in the nasal cavity. They comprise 
less than 1% of the nasal malignancies [26] Multivariate analysis 
was carried out using cause-specific survival rates. Independently 
important prognostic factors at initial treatment were age at diagnosis, 
extra thyroidal invasion, and degree of differentiation histological for 
papillary cancers; and extra thyroidal invasion, distant metastases, 
primary tumor size, nodal involvement, age at diagnosis, and 
postoperative status for follicular cancers [27].
Patients with follicular thyroid cancer, when first examined, 
usually have solitary thyroid nodules that are follicular neoplasms by 
aspiration cytology, and these nodules fail to regress in response to 
TSH-suppressive therapy. Frozen section rarely aids in management 
the preferred treatment for follicular neoplasm’s is lobectomy followed 
by completion total thyroidectomy for histological proven carcinomas 
larger than 1.0 cm. Total thyroidectomy allows use of thymoglobulin 
and radioiodine scanning to detect and treat metastatic disease. 
Complications of thyroidectomy were uncommon, and the mortality 
rate in treated patients was relatively low [28] Most appropriate 
individualized treatment planning approach all factors such as tumor 
and, tumor range of motion and patient tolerance toward the treatment 
technique need to be assessed [29].
Medullary Thyroid cancer
Unlike papillary and follicular thyroid cancers which arise from 
thyroid hormone producing cells, medullary cancer of the thyroid 
originates from the parafollicular cells (also called C cells) of the 
thyroid. Patients with clinically evident Medullary thyroid cancer 
should have a total extra capsular thyroidectomy with bilateral central 
neck dissection and therapeutic modified (functional) radical neck 
dissection when the primary tumor is greater than 1 cm and when 
the central neck nodes are positive [30]. Medullary thyroid cancer is 
a tumor of the thyroid C cells that occurs in sporadic and hereditary 
clinical settings. Genetic testing of at-risk individuals is available and 
has been applied to patient management. Plasma calcitonin levels are a 
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very sensitive marker for the presence of disease. Surgery offers the best 
hope for cure and also is an effective modality for managing metastatic 
and recurrent disease [31].
The goal in managing patients who have MTC is to detect and 
surgically remove disease at an early stage. Tumor marker-based 
biochemical screening and DNA-based genetic screening have created 
the opportunity for effective prophylactic surgery in patients at risk 
for hereditary MTC. Complete surgical resection is critical for cure 
because cervical reoperation for persistent or recurrent disease benefits 
only select patients. With the advent of therapies that target the RET-
activated pathways, new hope may be emerging for patients who have 
locally advanced or metastatic disease [32].The method of choice for 
screening the screening method presented here is capable of confirming 
the presence of the disease [33] multiplexed functional screening which 
is based on imaging multiple targets in the physiologic context of intact 
cells by extraction of multicolor fluorescence information [34].
It can be sporadic as well as hereditary. The histological classification 
nowadays is increasingly performed immune histological via calcitonin. 
Clinically the tumor ranges from the very small, but hormonally 
highly active form, to the aggressive, mostly undifferentiated form 
[35].Study confirms that MTC is not an infrequent finding among 
patients with thyroid nodules (nearly 1 in 250 patients). In addition, 
screening thyroid nodules with serum calcitonin measurement allows 
the diagnosis and treatment of MTC at an earlier stage, resulting in a 
better outcome compared with MTC not detected by serum calcitonin 
measurement. One of the reasons for this finding is that increasing 
the preoperative diagnostic accuracy of MTC prompts the surgeon 
to perform a more radical and possibly curative treatment. On this 
basis, routine measurement of basal serum calcitonin levels should 
be considered an integral part of the diagnostic evaluation of thyroid 
nodules [36].
Anaplastic Thyroid cancer
Anaplastic thyroid carcinoma is one of the most aggressive 
malignancies, with a poor prognosis. Although rare, representing only 
2% of clinically recognized thyroid cancers, the overall median survival 
is limited to months. Most patients are elderly and seek treatment with 
a rapidly growing mass. Almost half the patients seek treatment with 
distant metastases, with as many as 75% developing distant disease 
during their illness. In most the patients, complete surgical resection is 
not possible. There are, however, a few patients with disease reported 
in the literature who has demonstrated long-term survival with 
aggressive multimodal therapy that included surgery, radiation, and 
chemotherapy [37].
Anaplastic thyroid carcinomas (ATCs) are highly aggressive, 
extremely lethal human cancers with poor therapeutic response. 
Chemokines are a super family of small cytokine-like proteins 
.Some recent studies suggest that many of these pro-inflammatory 
Chemokines and their receptors are the products of proto-oncogene’s 
or tumor suppressor pathways in many cancers. An understanding 
of this axis may enable researchers to develop targeted strategies for 
cancer [38].  Factors controlling tumor angiogenesis are varied and 
currently under investigation. Chemokines, which produced by both 
tumor cells and cells of tumor microenvironment are known with a 
role in tumor angiogenesis [39].
Although the majority of thyroid cancer patients presenting to 
our surgical endocrinology clinics present with and often curable 
disease, patients may rarely present with a history and physical 
findings suggestive of an Anaplastic thyroid cancer. The endocrine 
surgeon should recognize, diagnose, and treat this patient urgently 
and promptly. The clinical course and findings from two patients who 
presented to our endocrine surgery clinic recently are summarized 
below from the patients’ clinical notes [40].
No effective treatment options currently are available to patients 
with Anaplastic thyroid cancer (ATC), resulting in high mortality rates. 
Epidermal growth factor (EGF) has been shown to play a role in the 
pathogenesis of many types of cancer, and its receptor (EGFR) provides 
an attractive target for molecular therapy [41]. Receptors are members 
of the six broad groups of oncogenic products that under finely 
tuned conditions play crucial biological roles in cell differentiation, 
organogenesis, development, tissues repair and apoptosis. These 
molecules have been conserved along the evolution and appear to be 
irreplaceable for the multiplicity and survival of organisms [42].
Targeting epidermal growth factor receptor (EGFR) is a promising 
approach to increasing radio sensitivity of head and neck cancers 
but treatment resistance remains an important clinical problem. 
Combining epidermal growth factor receptor inhibitors with radiation 
has been shown to be more effective than either treatment alone for 
head and neck carcinoma in multiple preclinical studies [43].
Treatment for Thyroid cancer
Thyroid hormone replacement
Many people have a thyroid gland that cannot make enough 
thyroid hormone for the body’s needs. This is called Hypothyroidism 
and may be caused by a non-functioning thyroid gland (for example 
Hashimoto’s disease), by destruction of thyroid gland by surgery 
or radiation treatment or by a non-functioning pituitary gland. 
Hypothyroidism is the most common reason for needing thyroid 
hormone replacement. Advanced verification of complete surgical and 
medical evaluations may minimize this event [44]. Radiation therapy 
is a complex radiotherapy technique which allows delivering radiation 
dose conforming to complex shaped target volumes and at the same 
time efficiently sparing the surrounding normal/healthy structure. 
Thus it is the treatment of choice for curative radiotherapy [45].
Hypothyroidism is an endocrine disorder affecting 1%–10% of 
the global population. Hypothyroidism is defined as an inadequate 
production of thyroid hormones by the thyroid gland and can cause 
numerous symptoms including fatigue, weakness, weight gain, and 
depression. Experimental studies and clinical data have demonstrated 
that thyroid-cell proliferation is dependent on thyroid-stimulating 
hormone (TSH), thereby providing the rationale for TSH suppression 
as a treatment for differentiated thyroid cancer. Several reports have 
shown that hormone-suppressive treatment with the L-enantiomer of 
tetraiodothyronine (L-T4) benefits high-risk thyroid cancer patients 
by decreasing progression and recurrence rates, and cancer-related 
mortality [46].
Radiotherapy
Surgery is the most effective treatment for thyroid cancer; however, 
in some subsets of patients, the role of radiotherapy (RT) is important. 
The main indication for external-beam RT is incomplete surgery. When 
neoplastic tissue is left behind at operation, RT must be considered, 
but only if an experienced surgeon feels that everything that can be 
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done has been done. Generally, in those patients, the neoplastic tissue 
involves the larynx, trachea, esophagus, blood vessels or mediastinum 
[47].
Radiotherapy is a common treatment for cancer, but failure is 
observed 30 to 40% of the time. It is more common in patients with 
abnormal p53. The phytochemical diferuloylmethane (curcumin) a 
naturally occurring flavanoid derived from the rhizome of Curcuma 
longa shows potential radio sensitizing effects. The expression of p53 
and p53 target genes was examined using RNase protection assay and 
Western blot analysis. Cell cycle and apoptosis was evaluated by flow 
cytometry. Cell viability and colony formation was examined using 
MTT assay and clonogenic assay respectively [48] the p53 mutations 
observed in tumors represent the expression of such instability by 
allowing the accumulation of genetic alterations caused by multiple 
mechanisms [49].
The ionizing radiation technique was used in several countries 
mainly for the sterilization of health care [50].Radiation effects are 
mainly associated with the chemical changes but also depended 
on physical and physiological factors Dose rate, dose distribution, 
radiation quality, radiation type and exposure pattern are important 
physical parameters and also depends on physiological factors like 
growth phase, sensitivity [51].
Radioactive iodine
Radioactive iodine, given in a liquid form, is absorbed and 
concentrated by the thyroid gland. The treatment destroys thyroid 
tissue but does not harm other tissue in the body. Radioactive iodine 
(RAI) has been used in the treatment of thyroid malignancy for over 
60 years. Several side effects of RAI administration are well known 
Xerostomia occurs in roughly 50% of patients receiving and is known 
to occur in a dose-dependent fashion. 
Common ocular complications include chronic or recurrent 
conjunctivitis, dry eye syndrome, and xerophthalmia, which has been 
reported to occur in 23% of patients receiving radioiodine treatment 
for malignancy the use of radioactive iodine for the management of 
well-differentiated thyroid cancer, is greatly increasing [52]. Dry eye 
syndrome is a chronic lack of sufficient lubrication and moisture on 
the surface of the eye. Its consequences range from subtle but constant 
irritation to ocular inflammation of the anterior tissues of the eye [53]. 
Conjunctivitis is a local allergic condition centered mainly in the ocular 
area, although sometimes it is also associated with rhinitis. The disease 
ranges in severity from mild to severe forms [54].
Radioactive iodine is a form of iodine chemically identical to 
nonradioactive iodine. Therefore, the thyroid gland, which takes up 
iodine to make thyroid hormone, cannot distinguish between the 
two. Radioactive iodine remnant ablation destroys residual thyroid 
tissue after surgical resection of papillary or follicular thyroid cancer. 
Radioactive iodine ablation may be beneficial in decreasing recurrence 
of well-differentiated thyroid cancer [55]. There has been some 
controversy with regards to which preparation of radioactive iodine 
should be used [56].
Recent advances in diagnosis and treatment of cancer have led to 
an increase in cancer survival and hence, there is a greater emphasis on 
quality beside quantity of survival [57].
Chemotherapy
Chemotherapy involves the use of anticancer drugs to kill cancer 
cells. Some patients who receive chemotherapy for thyroid cancer may 
also need external radiation therapy. When it is used to treat people 
with thyroid cancer, chemotherapy may result in side effects such as 
an increased risk of infection, fatigue, hair loss, poor appetite, nausea, 
and vomiting. Post operative nausea and vomiting occurs in as many 
as 70%-80% of high risk surgical patients [58] these findings suggested 
that combination therapy with these agents may provide enhanced 
therapeutic response in cancer patients [59].
Cancer chemotherapy aim is to minimize the tumor burden at the 
end of the treatment period while maintaining a normal cell population 
above a lower level as a limit of toxicity [60]. Cancer is the state of cells 
marked by unregulated proliferation. There are several characteristic 
features attributed to its occurrence [61]. A growing interest in the 
use of adult stem cells for the treatment of several cancers has been 
developed over the last few years [62] the cancer stem cell theory 
has emerged as a paradigm shift in our understanding of cancer as a 
disease of stem cells. A small subset of cancer cells within the tumor 
mass has the exclusive capacity to divide and expand the CSC pool and 
to differentiate into non tumorigenic, more differentiated cancer cell 
lineages. The existence of these small subsets of cells is responsible for 
tumor recurrence and metastasis [63].
Several factor both inside and outside of the body may contribute 
to the development of many cancer types. Many human organs take 
several years to turn as malignant and have many causes [64] about 
9% of the incident thyroid cancers could be attributed to prior head 
and neck irradiation, 4% to goiter, and 17% to thyroid nodular disease, 
leaving the etiology of most thyroid cancers yet to be explained [65]. 
Different chemotherapeutic agents and regimens are being tried to 
evaluate best outcomes [66].
Tumor cell invasion and metastasis is a compounding problem in 
cancer management, with therapeutic intervention of tumor invasion 
becoming recognized as an increasingly relevant clinical factor [67]. 
Current research on diseases of the ear, nose, throat and related 
structures of the head and neck has experienced significant strides in 
areas including cancer, otology, rhinology and laryngology. Molecular 
diagnostics and advanced imaging modalities including positron 
emission tomography have facilitated diagnosis and patient outcomes. 
Collaborations between physicians and laboratory researchers working 
to identify key clinical issues and translating the biological insights into 
novel therapeutic approaches are crucial to significant progress in the 
field [68].
Conclusion
In conclusion, our study indicates that thyroid cancer in patients 
is rather advanced at initial examination and usually associated with 
thyroid nodules. Most often the first symptom of thyroid cancer is a 
nodule in the thyroid region of the neck .Radioiodine treatment, and 
thyroid suppressive therapy represent an effective combination of 
treatments for this disease and allow a good quality of life. Over the 
long term, for tumors that are not initially metastatic to distant sites, 
the above treatment is found to be effective and confers a distinct 
outcome advantage. This therapy reduces tumor recurrence and 
mortality sufficiently to offset the augmented risks incurred by delayed 
therapy, at the time of diagnosis, and tumors that are much larger than 
1.5 cm, or regionally metastatic.
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